Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
51 papers
Recent·Most cited
B. B. Larsen, T. McMahon, J. T. Brown, Z. Wang, C. E. Radford, J. E. Crowe, D. Veesler, J. D. Bloom
This study uses deep mutational scanning to analyze how mutations in the Nipah virus receptor-binding protein affect function, receptor binding, and antibody escape, revealing constrained regions and limited antigenic variation in natural strains.
Cell · May 1, 2025Peer-reviewedEvolutionary Biology
M. McCallum, Y.-J. Park, C. Stewart, K. R. Sprouse, J. Brown, M. A. Tortorici, C. Gibson, E. Wong, M. Ieven, A. Telenti, D. Veesler
This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.
Cell · Aug 1, 2024Peer-reviewedBiochemistry
A. Addetia, C. Stewart, A. J. Seo, K. R. Sprouse, A. Y. Asiri, M. Al-Mozaini, Z. A. Memish, A. Alshukairi, D. Veesler
This study maps immunodominant sites on MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans, showing peak neutralizing activity against S1 and RBD epitopes.
bioRxiv · Mar 31, 2024Immunology
M. Rexhepaj, Y.-J. Park, L. Perruzza, D. Asarnow, M. McCallum, K. Culap, C. Saliba, G. Leoni, A. Balmeli, C. Yoshiyama, M. S. Dickinson, J. Quispe, J. T. Brown, M. A. Tortorici, K. R. Sprouse, , D. Veesler
The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.
bioRxiv · Mar 27, 2024 · PreprintBiochemistry
C. W. Chao, K. R. Sprouse, M. C. Miranda, N. J. Catanzaro, M. L. Hubbard, A. Addetia, C. Stewart, J. T. Brown, A. Dosey, A. Valdez, R. Ravichandran, G. G. Hendricks, M. Ahlrichs, C. Dobbins, A. Hand, , N. P. King
This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.
bioRxiv · Mar 13, 2024Immunology
J. Lee, C. Stewart, A. Schaefer, E. M. Leaf, Y.-J. Park, D. Asarnow, J. M. Powers, C. Treichel, D. Corti, R. Baric, N. P. King, D. Veesler
This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.
bioRxiv · Dec 12, 2023Biochemistry
Q. Zhao, S. Bertolli, Y.-J. Park, Y. Tan, K. J. Cutler, P. Srinivas, K. L. Asfahl, C. Fonseca Garcia, L. A. Gallagher, Y. Li, Y. Wang, D. Coleman-Derr, F. DiMaio, D. Zhang, S. B. Peterson, , J. D. Mougous
This study identifies umbrella toxin particles produced by Streptomyces that inhibit the growth of competing bacterial species, distinct from small molecule antibiotics.
bioRxiv · Dec 9, 2023 · PreprintMicrobiology
M. A. Tortorici, A. Addetia, A. J. Seo, J. Brown, K. Sprouse, J. Logue, E. Clarke, N. Franko, H. Chu, D. Veesler
This study shows that immune imprinting from prior Wuhan-Hu-1 spike exposure persists after XBB.1.5 vaccine booster, with neutralizing antibodies dominated by pre-existing memory B cells.
bioRxiv · Nov 28, 2023 · PreprintImmunology
B. Dadonaite, J. Brown, T. E. McMahon, A. G. Farrell, D. Asarnow, C. Stewart, J. Logue, B. Murrell, H. Y. Chu, D. Veesler, J. D. Bloom
This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.
bioRxiv · Nov 13, 2023Microbiology
A. Khmelinskaia, N. P. Bethel, F. Fatehi, A. Antanasijevic, A. J. Borst, S.-H. Lai, J. Y. Wang, B. Basu Mallik, M. M. Miranda, A. M. Watkins, C. Ogohara, S. Caldwell, M. Wu, A. J. R. Heck, D. Veesler, , N. P. King
This study shows that structural flexibility in computationally designed protein assemblies leads to multiple architectures, expanding their functional possibilities.
bioRxiv · Oct 18, 2023Bioengineering
C.-B. Ma, C. Liu, Y.-J. Park, J. Tang, J. Chen, Q. Xiong, J. Lee, C. Stewart, D. Asarnow, J. Brown, M. A. Tortorici, X. Yang, Y.-H. Sun, Y.-M. Chen, X. Yu, , H. Yan
The paper identifies two European bat MERS-related coronaviruses that use ACE2 as their receptor, revealing a distinct binding mode and host tropism determinants.
bioRxiv · Oct 2, 2023Microbiology
J. Lee, S. Zepeda, Y.-J. Park, A. L. Taylor, J. Quispe, C. Stewart, E. M. Leaf, C. Treichel, D. Corti, N. P. King, T. N. Starr, D. Veesler
This study characterizes the receptor tropism and antigenicity of a clade 3 sarbecovirus, identifying broad ACE2 usage and cross-neutralizing antibodies with implications for vaccine design.
bioRxiv · Sep 12, 2023Biochemistry
Q. Dowling, Y.-J. Park, N. Gerstenmaier, E. Yang, A. Wargacki, Y. Hsia, C. Fries, R. Ravichandran, C. Walkey, A. Burrell, D. Veesler, D. Baker, N. King
The paper designs large pseudosymmetric protein nanoparticles using a hierarchical computational method, achieving sizes up to 96 nm with 960 subunits.
bioRxiv · Jun 16, 2023 · PreprintBioengineering
D. Ellis, A. Dosey, S. Boyoglu-Barnum, Y.-J. Park, R. Gillespie, H. Syeda, Y. Tsybovsky, M. Murphy, D. Pettie, N. Matheson, S. Chan, G. Ueda, J. Fallas, L. Carter, B. Graham, , N. P. King
This study shows that antigen spacing on protein nanoparticles affects antibody responses to vaccination, with decreased spacing improving hemagglutination inhibition and neutralization potency.
bioRxiv · May 23, 2023Immunology
B. Burke, S. Rocha, S. Zhan, M. Eckley, C. Reasoner, A. Addetia, J. Lewis, A. C. Fagre, P. Charley, J. A. Richt, S. R. Weiss, R. Tjalkens, D. Veesler, T. Aboellail, T. Schountz
This study shows Jamaican fruit bats are poorly susceptible to SARS-CoV-2 but develop a regulatory T cell-like immune response when transduced with human ACE2, leading to lung infection without overt disease.
bioRxiv · Feb 13, 2023Microbiology
Y. Feng, M. Yuan, J. M. Powers, M. Hu, J. E. Munt, P. S. Arunachalam, S. R. Leist, L. Bellusci, L. E. Adams, S. Sundaramurthy, L. M. Shirreff, M. L. Mallory, T. D. Scooby, A. Moreno, D. T. OHagan, , B. Pulendran
This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.
bioRxiv · Jan 19, 2023 · PreprintImmunology
R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli
The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.
bioRxiv · Sep 30, 2022Immunology
T. N. Starr, A. J. Greaney, C. M. Stewart, A. C. Walls, W. W. Hannon, D. Veesler, J. D. Bloom
This study uses deep mutational scanning to analyze how mutations in the Omicron BA.1 and BA.2 RBDs affect ACE2 binding, RBD folding, and antibody escape, identifying epistatic shifts and lineage-specific changes.
bioRxiv · Sep 20, 2022Microbiology
A. Muenks, S. Zepeda, G. Zhou, D. Veesler, F. DiMaio
This paper develops a tool to automatically determine ligand structures from cryoEM maps and evaluates its accuracy across EMDB data.
bioRxiv · Aug 16, 2022Biochemistry
J. S. Low, J. Jerak, M. A. Tortorici, M. McCallum, D. Pinto, A. Cassotta, M. Foglierini, F. Mele, R. Abdelnabi, B. Weynand, J. Noack, M. Montiel-Ruiz, S. Bianchi, F. Benigni, N. Sprugasci, , F. Sallusto
The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.
bioRxiv · Mar 30, 2022Immunology
P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran
This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.
bioRxiv · Mar 18, 2022 · PreprintImmunology
J. E. Bowen, K. R. Sprouse, A. C. Walls, I. G. Mazzitelli, J. K. Logue, N. M. Franko, K. Ahmed, A. Shariq, E. Cameroni, A. Gori, A. Bori, C. M. Posavad, J. M. Dan, Z. Zhang, D. Weiskopf, , D. Veesler
This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.
bioRxiv · Mar 15, 2022 · PreprintImmunology
T. N. Starr, A. J. Greaney, W. W. Hannon, A. N. Loes, K. Hauser, J. R. Dillen, E. Ferri, A. Ghez Farrell, B. Dadonaite, M. McCallum, K. A. Matreyek, D. Corti, D. Veesler, G. Snell, J. D. Bloom
The paper analyzes epistatic shifts in SARS-CoV-2 RBD mutations across variants to understand how they influence ACE2 binding and future evolution.
bioRxiv · Feb 24, 2022Microbiology
H. Malhi, L. J. Homad, Y.-H. Wan, B. Poudel, B. Fiala, A. J. Borst, J. Y. Wang, C. Walkey, J. Price, A. Wall, S. Singh, Z. Moodie, S. Handa, C. Correnti, B. L. Stoddard, , A. McGuire
This study evaluates a nanoparticle vaccine displaying EBV gH/gL, showing it protects humanized mice against lethal EBV challenge, while monomeric gH/gL does not.
bioRxiv · Feb 17, 2022Immunology
A. C. Walls, L. A. VanBlargan, K. Wu, A. Choi, M. J. Navarro, D. Lee, L. Avena, D. M. Berrueta, M. N. Pham, S. Elbashir, M. C. Miranda, E. Kepl, M. Johnson, A. Blackstone, K. R. Sprouse, , D. Veesler
This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.
bioRxiv · Feb 7, 2022Immunology
A. Addetia, Y.-J. Park, T. Starr, A. J. Greaney, K. Sprouse, J. E. Bowen, S. W. Tiles, W. C. Van Voorhis, J. D. Bloom, D. Corti, A. C. Walls, D. Veesler
The paper examines structural changes in the SARS-CoV-2 spike E406W mutant that reduce neutralization by a monoclonal antibody cocktail and alters epitope recognition.
bioRxiv · Jan 21, 2022Biochemistry
M. McCallum, N. Czudnochowski, L. E. Rosen, S. K. Zepeda, J. E. Bowen, J. R. Dillen, A. Powell, T. Croll, J. Nix, H. W. Virgin, D. Corti, G. Snell, D. Veesler
This study determines the structural basis of SARS-CoV-2 Omicron's immune evasion and receptor engagement through cryo-EM and X-ray crystal structures of the spike and RBD bound to antibodies and ACE2.
bioRxiv · Dec 28, 2021Biochemistry
J. E. Bowen, A. C. Walls, A. Joshi, K. R. Sprouse, C. Stewart, M. A. Tortorici, N. M. Franko, J. K. Logue, I. G. Mazzitelli, S. W. Tiles, K. Ahmed, A. Shariq, G. Snell, N. T. Iqbal, J. Geffner, , D. Veesler
This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.
bioRxiv · Dec 19, 2021 · PreprintImmunology
A. C. Walls, K. R. Sprouse, A. Joshi, J. E. Bowen, N. Franko, M.-J. Navarro, C. Stewart, M. McCallum, E. A. Goecker, E. J. Degli-Angeli, J. Logue, A. Greninger, H. Chu, D. Veesler
The paper examines antibody responses in Delta breakthrough infections, finding they are more potent, durable, and broad compared to vaccinated-only or infected-only individuals.
bioRxiv · Dec 8, 2021 · PreprintImmunology
M. A. Tortorici, A. C. Walls, A. Joshi, Y.-J. Park, R. T. Eguia, T. Stevens-Ayers, M. J. Boeckh, A. Talenti, A. Lanzavecchia, D. Corti, J. D. Bloom, D. Veesler
The paper determines the structure of the CCoV-HuPn-2018 spike glycoprotein, identifies its receptor, and shows cross-neutralizing antibodies against related coronaviruses.
bioRxiv · Oct 25, 2021Microbiology